Pharmacology & Medication Management Flashcards

A study drug is administered as a prodrug that requires hepatic conversion to its active metabolite. A participant with Child-Pugh Class C cirrhosis enrolls. What is the primary concern?

Answer: Impaired prodrug activation leading to reduced efficacy

Severe hepatic impairment reduces the enzymatic capacity to convert prodrugs to active forms, potentially rendering the drug ineffective in participants with Child-Pugh C cirrhosis.

An investigator conducts a study in elderly participants (mean age 78). Compared to younger adults, which pharmacokinetic change is most consistently observed in this population?

Answer: Decreased renal clearance and prolonged drug half-life

GFR declines approximately 1% per year after age 40, making reduced renal clearance the most consistent and clinically significant PK change in elderly populations.

In a trial of a topical dermatological agent, systemic absorption is measured to assess safety. The bioavailability is 3%. A participant applies the cream to 40% of their body surface (BSA) due to widespread psoriasis instead of the protocol-specified 10% BSA. What is the safety concern?

Answer: Disproportionate systemic exposure due to increased absorption surface area

Systemic absorption of topical drugs correlates with surface area of application; applying to 4× the protocol BSA can lead to significantly higher systemic exposure and potential systemic toxicity.

A vaccine trial uses an aluminum adjuvant formulation. A participant asks why the adjuvant is included. Which is the most pharmacologically accurate explanation?

Answer: Adjuvants enhance and prolong the immune response to the antigen

Aluminum adjuvants create a depot effect at the injection site and activate innate immunity via NALP3 inflammasome signaling, potentiating and prolonging adaptive immune responses to co-administered antigens.

A Phase III trial uses a surrogate endpoint (LDL-C reduction) rather than a clinical outcome (MI, CV death). What is the primary regulatory concern with surrogate endpoints?

Answer: The surrogate may not reliably predict the clinical outcome of interest

Surrogate endpoints can be approved under accelerated pathways but must be reasonably likely to predict clinical benefit; history shows some surrogates (e.g., antiarrhythmic-induced PVC suppression) do not translate to improved clinical outcomes.

An investigational monoclonal antibody has a volume of distribution (Vd) of 4 L in a 70 kg participant. What does this indicate about the drug's distribution?

Answer: The drug is largely confined to plasma and does not distribute into tissues

A Vd of approximately 4 L approximates plasma volume, indicating that large molecules like monoclonal antibodies remain predominantly in the vascular compartment due to their size.

A trial protocol requires participant fasting for 10 hours before each dose of an oral study drug. A participant reports eating a high-fat meal 2 hours before dosing. What pharmacokinetic parameters are most likely affected?

Answer: Tmax delayed and Cmax altered due to slower gastric emptying with food

High-fat meals delay gastric emptying, slowing drug absorption and delaying Tmax; Cmax and AUC may increase or decrease depending on whether the drug has enhanced or reduced absorption with food.